A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancer

Rui Zhou a, Dongqiang Zeng a, Jingwen Zhang b, Huiying Sun a, Jianhua Wu a, Nailin Li c, Li Liang d,e,f, Min Shi a, Jianping Bin g, Yulin Liao g, Na Huang a,s, Wangjun Liao a,b,s

a Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China
b Department of Medicine-Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China
c Department of Pathology, Southern Medical University, Guangzhou, Guangdong, PR China
d Department of Pathology, Southern Medical University, Guangzhou, Guangdong, PR China
e Department of Medicine-Solna, Clinical Pharmacology Group, Karolinska University Hospital-Solna, Karolinska Institutet, Stockholm, Sweden
f Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China
g Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, Guangdong, PR China
h Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China

A R T I C L E   I N F O

Article history:
Received 5 January 2019
Received in revised form 18 February 2019
Accepted 15 March 2019
Available online 24 March 2019

Keywords:
TMRS
Colon cancer
Prognosis
Adjuvant chemotherapy
Immunotherapy

A B S T R A C T

Background: Tumour microenvironment (TME) is critical for the regulation of cancer development as well as therapy. The objective of the current study was the development of a robust prognostic model based on TME-relevant genes.

Methods: Five public microarray datasets providing clinical information were obtained. The least absolute shrinkage and selection operator regression method was used to reduce the dimensionality of robust prognostic genes identified via the bootstrap method.

Findings: We established a prognostic panel, designated as tumour microenvironment risk score (TMRS), consisting of 100 genes. With specific risk score formulae, the TMRS panel possesses a strong ability to predict relapse-free survival and overall survival through both univariate and multivariate analyses. Compared with the TNM stage, the TMRS panel showed much higher predictive accuracy. Further analysis revealed that patients with higher TMRS scores exhibited no therapeutic benefit from adjuvant chemotherapy, probably due to the activation of stromal relevant pathways and infiltration of stromal cells. Besides colon cancer, the TMRS panel was also revealed to be a reliable tool for prognostic prediction and chemotherapeutic decision-making in gastric cancer. Its value in predicting immunotherapy outcomes was also confirmed in two other cohorts consisting of metastatic urothelial carcinoma patients and melanoma patients.

Interpretation: Our TMRS panel may be an effective tool for survival prediction and treatment guidance in patients with stage I–III colon cancer.

Fund: This work was supported by the National Natural Science Foundation of China (No. 81772580) and Guangzhou Planed Project of Science and Technology (No. 201803010870).

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Colorectal cancer is a major source of morbidity and mortality worldwide [1]. Currently, the AJCC staging system and histologic classification remain the most important guidelines for stratifying patients and making clinical decisions [2]. However, due to the high levels of heterogeneity found in colon cancer, prognoses may vary widely between patients with similar clinical features. Therefore, in order to stratify patients more precisely, it becomes necessary to consider other prognostic factors in addition to clinical factors.

The tumour microenvironment (TME), consisting of multiple immune cells and stromal cells, is critical for the regulation of cancer initiation and development as well as cellular response to chemotherapy [3,4]. In recent years, the rise of immunotherapy, including immune checkpoint inhibitors, has shown assessment of TME landscape heterogeneity and reshaping of immune microenvironment to be promising avenues for future cancer management [5]. In colon cancer, assessing amounts of tumour-infiltrating lymphocytes based on IHC staining of CD3 and CD8, via an “immunoscore”, is considered an important supplemental marker in the TNM staging system for relapse and mortality prediction [6,7]. Unfortunately, the accuracy of prognosis prediction using
The heterogeneity of tumour microenvironment (TME) contains multiple dimensions of information on patient prognosis and treatment response. Currently, several signatures based on TME genes have been reported. However, as the genes included in these signatures were not all correlated with prognosis, the clinical predictability of these signatures was not satisfactory. In colon cancer, recent advances in high-throughput gene testing technology have led to the development of some molecular signatures for prognosis prediction and personalisation of treatment paradigms. However, to the best of our knowledge, none of these signatures were established based on TME-relevant genes. In addition, an immunoscore system has been developed based on IHC staining of CD3 and CD8. Unfortunately, the accuracy of prognosis prediction using the immunoscore system was found to be limited, as reported by the latest multi-central clinical research. Therefore, it is necessary to develop a novel TME-related prognostic model to improve predictive accuracy and identify patients for whom chemo- and immunotherapies may be more beneficial.

**Added value of this study**

We developed a robust prognostic panel utilising the machine learning method based on TME-relevant genes for stage I–III colon cancer patients, designated as the “tumour microenvironment risk score (TMRS)”. This panel not only accurately predicted relapse-free survival and overall survival among colon cancer patients, but also served as a biomarker for identifying patients that could potentially benefit from adjuvant chemotherapy. In addition to colon cancer, the TMRS panel was also revealed to be a reliable tool for prognostic prediction and chemotherapeutic decision-making in gastric cancer. Furthermore, we also found that the TMRS panel enabled prediction of anti-PD-L1 and anti-PD-1 immunotherapeutic outcomes in urothelial carcinoma patients and melanoma patients.

**Implications of all the available evidence**

The TMRS gene panel represents a potentially robust tool for survival prediction and treatment guidance in patients with stage I–III colon cancer and may also be applicable to other types of cancers.

---

The imunoscore system was found to be limited. A multi-center study (Supplement Table S1) included 12 published studies (16–27), which provided transcriptomic signatures for multiple immune and stromal cell populations. Robust prognostic genes were identified using two steps: first, we assessed the correlation between the relative expression value (z-transformed) of each gene and RFS using Cox univariate regression analysis in the entire cohort, where genes with $P < 0.05$ were selected for further analysis; next, we used bootstrapping to test the genes which passed initial filtering for robustness as follows: 70% patients randomly extracted from the training cohort were assessed for survival impact of their genes. This procedure was repeated 1000 times and the genes that were incorporated in 70% of resample runs (achieved $P < 0.05$ in robustness testing) were considered as robust prognostic genes and selected for further analysis.

**2. Materials and methods**

**2.1. Transcriptome data acquisition and pre-processing**

The Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) was searched for eligible colon cancer datasets that fulfilled the following criteria: samples were hybridised to the Affymetrix HG-U133 Plus 2.0 (GEO accession number GPL570) platforms; >50 stage I–III colon cancer patients were included in each dataset; and information on the TNM stage was available. In order to explore the role of our model in gastric cancer, we downloaded the “GSE62254” dataset, simultaneously containing RFS and OS information generated via the GPL570 platform. Finally, for the immunotherapeutic efficiency analysis, two transcriptomic datasets from patients with metastatic urothelial cancer (mUC) treated with anti-PD-L1 agents (atezolizumab, IMvigor dataset, retrieved via R software using “limma” package) [12], and patients with metastatic melanoma treated with anti-PD-1 agents ( pembrolizumab or nivolumab, GSE78220, downloaded from GEO website) were downloaded. Expression profiles of these two cohorts were generated via high throughput sequencing. Raw “CEL” files of microarray data were downloaded and normalised using a robust multiarray averaging method with “affy” and “simpleaffy” packages [13], RNA sequencing data was transformed using the “voom” algorithm in order to convert count data to values similar to those resulting from microarrays [14]. The “ComBat” algorithm was applied to reduce the likelihood of batch effects from non-biological technical biases. A summary of the information of all datasets used in this study is provided (Supplement Table S1).

**2.2. Study population and clinicopathological variables**

Samples were randomly separated into training and validation (7:3) sets for prognostic analyses based on cohorts, in order to identify and evaluate the models as we described before using “createDataPartition” function of the “caret” package [15]. Clinical information was retrieved using the “GEOquery” package for GEO datasets and the “limma” package for the IMvigor cohort. The endpoints analysed in this study were RFS, defined as the interval between the date of diagnosis and date of tumour relapse, and OS, defined as the interval between the date of diagnosis and death.

**2.3. Robust tumour microenvironment prognostic gene identification**

TME-relevant genes were obtained from 12 published studies (16–27), which provided transcriptomic signatures for multiple immune and stromal cell populations. Robust prognostic genes were identified using two steps: first, we assessed the correlation between the relative expression value (z-transformed) of each gene and RFS using Cox univariate regression analysis in the entire cohort, where genes with $P < 0.05$ were selected for further analysis; next, we used bootstrapping to test the genes which passed initial filtering for robustness as follows: 70% patients randomly extracted from the training cohort were assessed for survival impact of their genes. This procedure was repeated 1000 times and the genes that were incorporated in 70% of resample runs (achieved $P < 0.05$ in robustness testing) were considered as robust prognostic genes and selected for further analysis.

**2.4. TMRS gene panel generation using LASSO Cox regression**

The Cox regression model, with least absolute shrinkage and selection operator (LASSO) penalty, was implemented to reduce
dimensionality and select the most useful prognostic markers among the robust prognostic genes identified before [28,29]. Notably, all gene expression values were dichotomised before entering the LASSO Cox regression, and the “surv_cutpoint” function of the “survminer” R package was used to determine the optimal cut-off point of each gene based on the maximally selected log-rank statistics. Moreover, we set the “minprop” parameter of the “surv_cutpoint” function (referring to the minimal proportion of observations per group) to 30% to avoid the
occurrence of too few patients in a certain group. Genes represented by optimal values of the penalty parameter $\lambda$, which were determined by ten-fold cross-validations, constituted the TMRS panel in this study. Risk scores based on the TMRS panel were also constructed using the dichotomised expression value of selected genes (a value of one or two was given to represent an expression value higher or lower than the cut-off value) via a Cox regression analysis in the training cohort. Among these, the risk score was named TMRS-RFS when RFS was used as the endpoint variable to generate the cut-off values and analysed by Cox regression, and correspondingly, the risk score was named TMRS-OS when OS was used as the endpoint.

2.5. Estimation of immune infiltration

An immune infiltration estimation was conducted using the “Micro-environment Cell Populations-counter (MCP-counter)” method, which allows robust quantification of the absolute abundance of ten immune and stromal cell populations in heterogeneous tissues from transcriptomic data [18]. The R package “MCPCounter” was applied to achieve the transformation of mRNA data to the level of non-tumour cell infiltration in the tumour microenvironment, and gene expression profiles were prepared using standard annotation files prior to MCP-counter analysis. The stromal score, immune score, and tumour purity were estimated by applying the “ESTIMATE” R package developed by Yoshihara et al. [30](https://sourceforge.net/projects/estimateproject/).

2.6. Gene set variation analysis (GSVA)

GSVA is a gene set enrichment method that estimates the variation of pathway and biological process activity over a sample population in an unsupervised manner [31]. The gene set files of “c2.cp. kegg.v6.2.symbols” and “h.all.v6.2.symbols,” downloaded from the “Molecular Signatures Database,” were employed for GSVA using “GSVA” packages for R. The significance threshold was set at an adjusted $P < 0.05$.

2.7. Statistical analysis

The normality of the variables was tested via the Shapiro-Wilk normality test for comparisons of two groups. The statistical significance of differences between normally distributed variables was estimated using the unpaired Student’s $t$-test, and non-normally distributed variables were analysed via the Mann-Whitney $U$ test. For comparisons of more than two groups, Kruskal-Wallis and one-way ANOVA tests were used as non-parametric and parametric methods, respectively. Correlation was computed using Spearman’s and distance correlation analyses. Survival rates were calculated using the Kaplan–Meier method, and the significance of differences between survival curves was determined using the log-rank test. In regard to the heterogeneity between different types of cancers, the best cut-off values for each continuous prognostic marker were recalculated using the “survminer” R package separately for different tumour types. Uni- and multivariate analyses were performed using Cox proportional hazard models with the stepwise method “LR forward”. Nomogram construction and validation were performed using lasonos’ guide [32]. Survival predictive accuracy of prognostic models was assessed based on a time-dependent receiver operating characteristic curve (ROC) analysis and Harrell’s concordance index (c-index) analysis. All statistical analyses were conducted using the R software (version 3.5.0) and SPSS software (version 25.0) and $P$ values were two-tailed. Statistical significance was set at $P < 0.05$.

3. Results

3.1. Colon cancer patient characteristics and robust prognostic gene identification

A summary of the information of all datasets used in this study is provided (Supplemental Table S1). Detailed patient characteristics are listed (Supplemental Table S2). A total of 990 patients diagnosed with stage I–III colon cancer from five GEO datasets (GSE17538, GSE33113, GSE37892, GSE38832, and GSE39582) were retrospectively analysed in this study. The median age at diagnosis was 69·0 years (range, 22.0–97.0 years) and 481 (48.6%) of the patients were male. Among them, RFS information was available for 990 patients, wherein mean survival was 146 months. OS information was documented in 678 patients and the mean survival was 130 months. Through the 2-step analysis described in the “Materials and methods”, 1746 of 5952 genes passed the first filter and 797 genes, the expression levels of which were stably and significantly correlated with prognosis, were eventually identified and defined as robust prognostic genes (Supplemental Table S3).

3.2. Construction of molecular subgroups using TME-relevant robust prognostic genes

First, we used unsupervised clustering methods in order to classify 990 tumour samples into different molecular subgroups based on 797 robust prognostic genes. The “ConsensusClusterPlus” package was used to evaluate clustering stability and select the optimal cluster number. Two distant patient clusters, termed as the tumour microenvironment cluster 1 (TMEC1) and TMEC2, were finally identified (Fig. 1a–b), and comparison of the proportion of patients from different GEO series between two TMEC clusters showed no significant differences (Supplemental Table S4). Via the log-rank test, the Kaplan–Meier curve indicated significant survival differences between the two clusters for both OS (Fig. 1c) and RFS (Fig. 1d). We further focused on GSE39582 datasets, which provided the most comprehensive patient information, characterising biological and clinical differences among these clusters. Samples in TMEC2 exhibited a more advanced tumour stage and proficient mismatch repair (pMMR) status (Fig. 1e and Supplemental Table S5). No significant distribution difference was found in terms of the CpG island methylator phenotype, chromosome instability status, and genetic mutations (KRAS, BRAF, and P53). With regards to biological behaviour (Fig.1e), pathways involved in DNA replication and repair, oxidative phosphorylation (OXPHOS), cell cycle, and one carbon metabolism were activated in TMEC1 (favourable survival), whereas TMEC2 (worse survival), as expected, showed enrichment of pathways related to stromal activation and cancer progression, such as angiogenesis and epithelial-mesenchymal transition (EMT). As confirmed by subsequent cell infiltration analysis, TMEC2 patients showed an obvious increase in infiltration by stromal cells, including neutrophils, endothelial cells, and fibroblasts (Fig. 1f). Interestingly, it was also observed that in TMEC2 patients, the enrichment of immune relevant pathways was accompanied by an increase in the expression of immune checkpoint genes. Finally, the distribution of TMEC relative to that of other established colon cancer molecular subtypes was compared. The result demonstrated that TMEC2 patients were mainly
concentrated in the C4, C6, and CMS4 subtypes, mostly representing mesenchymal phenotypes, while TMEC1 patients were mainly concentrated in the C1, C3, and CMS2 subtypes, mostly displaying epithelial phenotype characteristics (Fig. 1g, Supplemental Table S5) [33,34].

3.3. Construction of prognostically relevant TMRS gene panel

In order to develop a gene panel practical for clinical use, we applied the LASSO Cox regression model to the 797 robust prognostic genes for dimension reduction. Patients were randomly regrouped into training and validation cohorts for prognostic analyses as described in the “Materials and methods” section. Comparison of patient characteristics between the two groups showed no significant differences (Supplemental Table S2). Through the LASSO model (Supplemental Fig. S2), we generated a TMRS gene panel consisting of 100 genes (Supplemental Table S6) and built two prognostic models using Cox analysis based on RFS (TMRS-RFS) and OS (TMRS-OS) information separately. Patients were stratified into two groups based on TMRS-RFS and TMRS-OS values, respectively, using a cut-off value calculated in the entire cohort (2·26 for TMRS-RFS and 3·02 for TMRS-OS). In both training and validation sets, Kaplan–Meier curves indicated that patients in the high-TMRS-RFS group had a significantly higher risk of relapse (Fig. 2a–b). In ROC (Fig. 2a–b) and c-index analyses (Table 1), the TMRS-RFS model showed a much higher predictive ability than that of the TNM stage, considered as a continuous variable, in the training and validation cohorts. Since stage is a categorical variable, we converted TMRS-RFS from continuous to three-classified variables to enhance comparability, and the superior predictive accuracy of TMRS-RFS was sustained even as a categorical variable (Supplemental Fig. S3a–c and Table 1). Using multivariate analysis, the TMRS-RFS model was also found to be a strong independent risk factor when treated as a continuous variable in all patient cohorts (Table 2). Similar results were also found for the TMRS-OS model in 678 patients with documented OS information (Fig. 2c, Supplemental Fig. S3d–e, Tables 1–2).

Table 1

| Cohort | TMRS-RFSa | TMRS-RFSb | TMRS-OSa | TMRS-OSb | Stagec,d |
|--------|------------|------------|----------|----------|---------|
| RFS    | 0.86 ± 0.02 | 0.82 ± 0.02 | /        | /        | 0.64 ± 0.02 |
|        | 0.80 ± 0.04 | 0.76 ± 0.03 | /        | /        | 0.63 ± 0.03 |
| OS     | 0.80 ± 0.02 | 0.75 ± 0.02 | 0.56 ± 0.02 |
| Entire |            |            |          |          |         |

Abbreviation: TMRS, tumour microenvironment risk score; RFS, relapse-free survival; OS, overall survival.
a Continuous variables.
b Category variables.
The predictive power of the TMRS-RFS and TMRS-OS models was next tested in various subgroups stratified by patient dataset, age, gender, stage, tumour site, and CMS subtype in the entire cohort, respectively, where TMRS-RFS and TMRS-OS were both analysed as continuous variables. Forest plots indicated that, for both models, a higher value could significantly identify the patients with worse prognoses in all subgroups (Fig. 2d–e).

### 3.4. TMRS panel predicts therapeutic benefit of chemotherapy in colon cancer

Adjuvant chemotherapy (ADJC) is the main treatment strategy for non-metastatic colon cancer patients [35]. Since only the GSE39582 dataset recorded chemotherapy information of patients, we analysed the relationship between the TMRS panel and ADJC benefits in this dataset, where OS was used as the treatment outcome. Survival benefits of low-TMRS-RFS and low-TMRS-OS were maintained regardless of ADJC conduction (Fig. 3a–b). Interestingly, it was observed that ADJC significantly reduced the mortality risk of patients only in low-TMRS-RFS and low-TMRS-OS groups but did not confer survival benefits to patients in high-TMRS-RFS or high-TMRS-OS groups (Fig. 3c). Furthermore, the results of stratified analysis of each stage (Supplementary Fig. S4), showed that treatment benefits of ADJC were higher for patients in groups with low scores, in either Stage II or III. To develop a clinically relevant quantitative method for predicting the probability of patient mortality, we constructed two nomograms (Fig. 3d). Univariate and multivariate survival analyses of TMRS-RFS, TMRS-OS and clinical variables.

|            | UVA (RFS) |                     | MVA (RFS) |                     | UVA (OS) |                     | MVA (OS) |
|------------|-----------|---------------------|-----------|---------------------|----------|---------------------|----------|
|            | Entire     | p-Value             | Entire     | p-Value             | Training | p-Value             | Validation | p-Value             | Entire     | p-Value             |
| Age        |            |                     |           |                     | NE       |                     | NE        |                     | 1.03       | (1.01–1.04)         | <0.001     |
| Gender     |            |                     |           |                     | NE       |                     | NE        |                     | 0.66       | (0.48–0.90)         | 0.009      |
| TMRS-RFS   | 0.73       | (0.59–0.90)         | 0.003     |                     | NE       |                     | NE        |                     | 1.74       | (1.09–2.73)         | <0.001     |
| TMRS-OS    | 3.12       | (2.13–2.58)         | <0.001    |                     | 2.70     | (2.33–3.13)         | <0.001    |                     | 0.015      | NE                   | NE         |
| Stage (vs. stage I) |          |                     |           |                     |          |                     |           |                     |            |                      |            |
| Stage II   | 8.24       | (2.03–33.39)        | 0.003     |                     |          |                     |           |                     |            |                      |            |
| Stage III  | 17.97      | (4.45–72.55)        | <0.001    |                     | 1.74     | (1.09–3.34)         | 0.097     |                     | 5.27       | (0.72–38.64)         | 0.101      |
| CMS (vs. CMS4) |        |                     |           |                     | 2.30     | (1.20–4.41)         | 0.012     |                     | 7.00       | (0.96–50.97)         | 0.055      |
| CMS1       | 0.55       | (0.35–0.86)         | 0.009     |                     |          |                     |           |                     |            |                      |            |
| CMS2       | 0.59       | (0.41–0.84)         | 0.003     |                     |          |                     |           |                     |            |                      |            |
| CMS3       | 0.422      | (0.25–0.73)         | 0.002     |                     |          |                     |           |                     |            |                      |            |

Abbreviation: TMRS, tumour microenvironment risk score; UVA, univariate analysis; MVA, multivariate analysis; RFS, relapse-free survival; OS, overall survival; CMS, consensus molecular subtypes; NE, not enter.

* Continuous variable.

3.5. Identification of TMRS-RFS and TMRS-OS related biological pathways and processes

The correlations between TMRS panel derived scores with clinical characteristics and molecular subtypes were further investigated in the GSE39582 series (Fig. 4a–b). In terms of clinical characteristics, both TMRS-RFS and TMRS-OS were increased in patients with more advanced stages and patients who had relapsed and died due to the disease. Furthermore, while gender influenced the value of TMRS-RFS, that of TMRS-OS varied between age and tumour site. In terms of molecular characteristics, we observed that KRAS mutation simultaneously up-regulated the values of TMRS-OS and TMRS-RFS, and patients in molecular subtypes C4, C6, and CMS4 exhibited significantly higher values of TMRS models than others. However, mismatch repair status was significantly correlated only with the TMRS-RFS level. Next, we used GSVA to study the association between potential biological phenotypes and the two TMRS models. The result showed that the biological behaviour of TMRS-OS and TMRS-RFS was similar to each other to some extent (Fig. 4c). The two models were both positively correlated with stromal activation relevant pathways, but negatively correlated with those of DNA replication and repair, OXPHOS, and one carbon metabolism. Cell infiltration analysis indicated that infiltration by multiple stromal cell types significantly increased with rising TMRS-OS and TMRS-RFS scores, while some immune cells, such as cytotoxic lymphocytes and NK cells, were negatively correlated with TMRS-RFS scores (Fig. 4d).

3.6. The TMRS panel could be used for prognostic prediction and tailoring therapies in gastric cancer

Reportedly, TME plays an important role in the initiation and progression of multiple tumour types [34]. Therefore, the current study investigated whether the TMRS panel can predict prognoses in patients with stage I–III gastric cancer. The GSE62254 series downloaded from GEO datasets indicated that in both OS (Fig. 5a) and RFS (Fig. 5b), TMRS panel derived scores were predictive of a poor outcome and acted as independent prognostic factors in gastric cancer patients (Supplemental Table S8). A subsequent ROC analysis further confirmed that the TMRS panel derived score models exhibited much better predictive accuracy in gastric cancer compared to those of the TNM stage (Fig. 5a–b). Additionally, we found that the TMRS-RFS model, but not the TMRS-OS model, could be used to screen gastric cancer patients who could benefit from ADJC (Fig. 5c–d). Subsequent cell infiltration (Fig. 5e) and GSVA analyses (Fig. 5f) showed that, compared with TMRS-OS model, the TMRS-RFS model in gastric cancer is markedly more related to stromal cell infiltration and the activation level of stromal-relevant biological processes, such as EMT and angiogenesis. Finally, the distribution of TMRS scores in patients of different ACRG subtypes was compared [36]. The result showed that both TMRS-OS and TMRS-RFS models have the highest scores in the “EMT” subtype, while the lowest score were observed in the “MSI” subtype (Fig. 5g).

3.7. TMRS panel predicts immunotherapeutic benefit

Currently, effective predictive markers for immune therapy are limited. The identification of novel predictive markers is crucial for further advancing precision immunotherapy. We retrieved two immunotherapy datasets (Invivgor210, GSE78220) with the transcriptome data released to explore whether TMRS panel could predict immunotherapeutic benefit. Invivgor210 documented expression data in human mUC samples from patients who did or did not respond to anti-PD-L1 immunotherapy, and GSE78220 is a malignant melanoma dataset of patients who received anti-PD-1 therapy. The Kaplan–Meier curve (Fig. 6a) revealed that a higher TMRS-OS value was associated with improved survival in patients who received anti-PD-L1 immunotherapy. The result showed that both TMRS-OS and TMRS-RFS models have the highest scores in the “EMT” subtype, while the lowest score were observed in the “MSI” subtype (Fig. 5g).
with much poorer survival in mUC patients who received immunotherapy. A violin plot further demonstrated that TMRS-OS values successively and significantly increased in patient groups with complete or partial response to stable disease and progressive disease (Fig. 6b). In total, 57 (46·3%) responders of immunotherapy in the low-risk group and 11 (6·3%) responders in the high-risk group ($P = 3 · 0 \times e^{-16}$, Chi square test, Fig. 6c) were identified. Notably, the TMRS-OS model enabled the classification of responders and non-responders with a considerably higher predictive power (AUC = 0·73) than both neoantigen (AUC = 0·77) and tumour mutation burden (TMB, AUC = 0·73). A complex model, combining the TMRS-OS, neoantigen, and TMB models using logistic regression, identified treatment response with a level of accuracy as high as 88% (Fig. 6d). PD-L1 expression in immune cells, but not tumour cells, was associated with the response of mUC patients towards anti-PD-L1 therapy [12]. Coincidently, a significant negative correlation between the TMRS-OS value and PD-L1 expression in immune cells was also observed (Fig. 6e). In addition, immune phenotype analysis demonstrated that the TMRS-OS value decreased with the activation of inflammation, although the $P$ value was not significant ($P = 0·280$, one-way ANOVA tests). The correlation
test showed a negative correlation between TMRS-OS and immune cell infiltration, TMB, and neoantigen, respectively. Unfortunately, infiltration of stromal cells was not significantly associated with TMRS-OS value (data not shown). Finally, the GSE78220 dataset was used to further verify predictive effect of TMRS panel on treatment outcome of melanoma immunotherapy. The result also showed that the TMRS panel could discriminate the prognoses of different patients (Supplemental Fig. S5a), and that patient scores were well connected to the treatment effect (Supplemental Fig. S5b–c), with the AUC reaching a value of 0.86 (Supplemental Fig. S5d). Of note, since information of only 27 patients was included in the GSE78220 series, the use of the TMRS panel containing 100 genes for the scoring might result in an overfitting problem. Thus, caution must be exercised when interpreting the relevant results.

4. Discussion

The heterogeneity of TME contains multiple dimensions of information on patient prognosis and treatment response. Currently, several signatures based on TME have been reported [20,21,37]. However, as the genes included in these signatures were not all correlated with prognosis, the prognostic prediction ability of these signatures were not satisfactory. In colon cancer, Galon et al [38] developed an immunoscore system based on the density of CD3⁺, CD8⁺, or
and fibroblasts. Meanwhile, the successive application of the bootstrap approach to quantify the expression (microarray) and the design of specific probes based on the sequences tested in the microarray chips are two necessary steps. Therefore, to make the TMRS signature more clinically applicable, we plan to use a nanostring technique to develop a microarray.

CD45RO⁺ lymphocytes in the central- and peri-tumor areas, as represented by the intensity of IHC staining, and found that the prognostic ability of the immunoscore was stronger than, and could potentially replace, the TNM stage. However, the latest multi-central clinical research reported that the accuracy of the immunoscore was only approximately 60% [6]. As such, although the prognostic ability of the immunoscore is higher than that of the TNM stage, there is still room for improvement in prediction accuracy. Neglecting the assessment of stromal cell infiltration may limit immunoscore prediction accuracy. When comparing the cell infiltration status of TMEC1 and TMEC2, we found that both stromal cell and immune cell infiltration significantly increased in the TMEC2 type, and the level of increase in the former was far higher than that of the latter. Further, the activation level of some stromal pathways may limit immunoscore prediction accuracy. When comparing the TMRS panel in gastric cancer cohort. (a–b) Kaplan–Meier curves (left) and ROC curves (right) of overall survival according to TMRS-OS groups (a) and relapse-free survival according to TMRS-RFS groups (b); (c–d) Kaplan–Meier curves of overall survival for gastric cancer patients in subgroups stratified by both TMRS-OS (c), TMRS-RFS (d), and receipt of adjuvant chemotherapy; (e) Bubble plot showing the correlations between TMRS-RFS, TMRS-OS values and cell infiltration in GSE62254 series; (f) Heatmap showing the correlation between TMRS-RFS, TMRS-OS and biological process in GSE62254 series; (g) Violin plot displayed the distribution of the TMRS-OS value (up) and TMRS-RFS value (down) in different ACRG molecular subtypes of gastric cancer. P-value for TMRS-OS comparison marked in red, and TMRS-RFS comparison marked in yellow. Boxes represent 25–75% of values, black lines in boxes represent mean values, and whiskers represent 1.5 interquartile ranges.

Chemotherapy is currently the main treatment strategy for cancer. Detecting patients that could potentially benefit from chemotherapy is an important step in precision treatment. Through analysis of the GSE39582 dataset, we found that the TMRS panel could effectively screen patients who were responsive to ADJC. Patients in the lower TMRS score group may benefit significantly more than patients in the higher TMRS score group. Several studies have reported that the EMT and angiogenesis are the main factors influencing the efficacy of chemotherapy [41–43]. Correspondingly, we found that the above-mentioned method to identify robust prognostic genes, and the machine-learning method, LASSO regression, to screen the optimal combination of genes, markedly raised the accuracy of the TMRS panel in predicting relapse and mortality risks in colon cancer patients. Thus, this model may have a strong clinical transformation value. However, microarrays based on whole transcriptomes are not practical clinically. According to the guidelines established by Altman et al. [40], before the gene signature is applied as a clinical grade assay, identification of an appropriate approach to quantify the expression (microarray) and the design of specific probes based on the sequences tested in the microarray chips are two necessary steps. Therefore, to make the TMRS signature more clinically applicable, we plan to use a nanostring technique to develop a gene detection kit based on these 100 genes and re-standardise the gene expression value and the cut-off value. Finally, only signatures validated in independent cohorts of patients with full clinical annotation could be applied clinically, which will be reported in a future paper. We will first validate the prognostic value of this model at our centre.
pathways were significantly more activated in colon cancer patients with higher TMRS scores than in patients with lower scores. This finding has also been confirmed in gastric cancer datasets where TMRS-RFS, with significant relevance to stromal pathway activation level, could be used to discriminate patients who could benefit from ADJC, while TMRS-OS, with no such significant relevance, did not display this function. Of note, due to limitation of the sample size in the datasets, additional prospective studies are required to further verify these findings.

Recently, clinical results from trials investigating checkpoint blockade inhibitors have attracted high interests in this therapeutic modality [5]. However, the selection criteria for candidates who are likely to benefit from such regimens requires further investigation. Encouragingly, the risk score generated by TMRS panel was also found to be predictive of outcome after anti-PDL1 in mUC and anti-PD1 in melanoma. The prediction accuracy of both patient cohorts reach approximately 85%, which is significantly higher than the tumour mutation burden and abundance of neoantigens models, which are biomarkers that predict patient’s response to immunotherapy [44, 45]. Currently, in colon cancer patients, the mismatch repair status is the only marker which predicts whether the patient should receive immunotherapy, and only patients with dMMR could possibly benefit [46]. As our study also revealed significant variation of the TMRS-RFS value between patients with different mismatch repair status, it may be speculated that immunotherapy might also be a preferable choice for patients in the low-TMRS-RFS group. Further investigation on the association between TMRS panel and immunotherapy efficiency in colon cancer patients are warranted.

There were some limitations to the present study. Firstly, the patient population was heterogeneous because of the retrospective nature of this study. Secondly, all colon cancer transcriptome profiling used for panel construction was produced by the GPL570 platform. Therefore, caution should be exerted when applying the panel to samples tested using platforms other than GPL570. Thirdly, since gene expression data was entered into Cox regression as categorical variables, the optimal cut-off value needs to be further verified in future studies.

In conclusion, the TMRS gene panel is a robust tool for survival prediction and treatment guidance in patients with stage I–III colon cancer. Further, prospective clinical trials are warranted to validate our findings.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.03.043.

Funding sources

This work was supported by the National Natural Science Foundation of China (No. 81772580 to Wangjun Liao) and Guangzhou Planned Project of Science and Technology (No. 201803010070 to Wangjun Liao).

Declaration of interests

The authors declare that they have no competing interests.

Author contributions

RZ, DZ and WL contributed to the planning of the study. RZ, DZ, NH and WL drafted the manuscript and revised the manuscript. NH verified the numerical results by an independent implementation. RZ, DZ, JZ, HS, and JW prepared all the figures and tables. LL, NL, MS, JB, and YL contributed to interpretation of data and review of the manuscript. All the authors reviewed and approved the final manuscript.
Availability of data and materials
GSE17538 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538); GSE33113 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33113); GSE37892 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37892); GSE38832 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38832); GSE39582 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39582); GSE62254 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62254); GSE78220 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78220); LimVigor210 R package “LimVigor210”.

Acknowledgements

The authors thank the members of W. Liao’s laboratory for advice and discussion.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1): 7–30.
[2] Hu H, Krainskas A, Willis J. Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Semin Oncol 2011;38(4):500–10.
[3] Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett 2015; 368(1):17–13.
[4] Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27(45):5904–12.
[5] Patel SA, Mino AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 2018;48(3):417–33.
[6] Pages F, Mlecnik B, Marlot F, Binde A, Ou FS, Bifulco C, et al. International validation of the consensus ImmunoScore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391(10135):2128–39.
[7] Wang Y, Lin HC, Huang MY, Shao Q, Wang ZQ, Wang FH, et al. The ImmunoScore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother 2018;67(3):455–64.
[8] Chen PF, Wang F, Zhang XZ, Nie JY, Liu L, Feng JR, et al. A novel gene-pair signature for relapse-free survival prediction in colon cancer. Cancer Manag Res 2018;10: 4145–53.
[9] Dai W, Feng Y, Mo S, Xiang W, Li Q, Wang R, et al. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer. Carcinogenesis 2018;39(10):1235–44.
[10] Dai W, Li Y, Mo S, Feng Y, Zhang L, Xu X, Yu X, et al. A robust gene signature for the prediction of early relapse in stage II–III colon cancer. Mol Oncol 2018;12(4):463–75.
[11] Sun D, Chen J, Liu J, Zhao G, Dong P, Wu B, et al. Establishment of a 12-gene expression signature to predict colon cancer prognosis. Peerj 2018;6:e4942.
[12] Mariahattan S, Turley SJ, Castello R, Guiney JG, GSF: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 2013;14:7.
[13] Iasonos A, Schlag D, Raj GV, Panagkos KS. How to build and interpret a nonogram for cancer prognosis. J Clin Oncol 2008;26(8):1364–70.
[14] Guiney DJ, Dienstmann R, Wang X, de Reynies A, Schlake K, Simon C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21(11):1350–6.
[15] Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10(5):e1001453.
[16] Wilkinson NW, Yothchers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 2010;17(4):595–66.
[17] Cristescu R, Lee J, Nebozyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer indicates gene subtypes associated with distinct clinical outcomes. Nat Med 2015;21(5):449–56.
[18] Hua D, Liu J, Chen M, Li J, Wang L, Li X, et al. Immunogenic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity. Clin Cancer Res 2018;24(15):3560–71.
[19] Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27(35):5944–51.
[20] Thrunnen DM, Schumacher TN. T cell dysfunction in cancer. Cancer Cell 2018;33(4): 70–82.
[21] Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012;9(5):e1001216.
[22] Cantelmo AR, Conradi LC, Brajic A, Covea J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 2016;30(6):968–75.
[23] Fischer KB, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527(7609):472–6.
[24] Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2012;13(10):714–26.
[25] Hellmann MD, Nathanson T, Rizvi HJ, Cmelecn BC, Sanchez-Vega F, Aluza A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 2018;33(5):843–52 e4.
[26] Schumacher TN, Schepfer W, Kvistborg P, Cancer Neoantigens. Ann rev of immunol 2019;37:173–200.
[27] Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 2015; 5(1):16–8.